Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease According to our (Global Info Research) latest study, the global Benign Prostatic Hyperplasia Therapeutics market size was valued at USD 6664.1 million in 2022 and is forecast to a readjusted size of USD 8338.4 million by 2029 with a CAGR of 3.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. The growth of the global benign prostatic hyperplasia therapeutics market is majorly driven by the increase in male geriatric population. Other factors boosting the market growth include rise in awareness about prostate cancer and other urological disorders and increase in occurrence of benign prostatic hyperplasia patients across the world. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hampers the market growth. Conversely, presence of strong pipeline products and high potential in untapped markets of the emerging economies are expected to provide lucrative growth opportunities for the global benign prostatic hyperplasia therapeutics market. This report is a detailed and comprehensive analysis for global Benign Prostatic Hyperplasia Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided. Key Features: Global Benign Prostatic Hyperplasia Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029 Global Benign Prostatic Hyperplasia Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029 Global Benign Prostatic Hyperplasia Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029 Global Benign Prostatic Hyperplasia Therapeutics market shares of main players, in revenue ($ Million), 2018-2023 The Primary Objectives in This Report Are: To determine the size of the total market opportunity of global and key countries To assess the growth potential for Benign Prostatic Hyperplasia Therapeutics To forecast future growth in each product and end-use market To assess competitive factors affecting the marketplace This report profiles key players in the global Benign Prostatic Hyperplasia Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH and Co. KG and Eli Lilly and Company, etc. This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence. Market segmentation Benign Prostatic Hyperplasia Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type Alpha Blocker 5-Alpha Reductase Inhibitor Phosphodiesterase-5 Inhibitor Others Market segment by Application Mono Drug Therapy Combination Drug Therapy Market segment by players, this report covers Abbott Laboratories Allergan plc Astellas Pharma Boehringer Ingelheim Pharma GmbH and Co. KG Eli Lilly and Company GlaxoSmithKline plc Merck and Co. Pfizer Sanofi Teva Pharmaceutical Industries Limited Market segment by regions, regional analysis covers North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific) South America (Brazil, Argentina and Rest of South America) Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa) The content of the study subjects, includes a total of 13 chapters: Chapter 1, to describe Benign Prostatic Hyperplasia Therapeutics product scope, market overview, market estimation caveats and base year. Chapter 2, to profile the top players of Benign Prostatic Hyperplasia Therapeutics, with revenue, gross margin and global market share of Benign Prostatic Hyperplasia Therapeutics from 2018 to 2023. Chapter 3, the Benign Prostatic Hyperplasia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast. Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029. Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Benign Prostatic Hyperplasia Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029. Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War Chapter 12, the key raw materials and key suppliers, and industry chain of Benign Prostatic Hyperplasia Therapeutics. Chapter 13, to describe Benign Prostatic Hyperplasia Therapeutics research findings and conclusion.
1 Market Overview 1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Therapeutics 1.2 Market Estimation Caveats and Base Year 1.3 Classification of Benign Prostatic Hyperplasia Therapeutics by Type 1.3.1 Overview: Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029 1.3.2 Global Benign Prostatic Hyperplasia Thera
